[{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"5d9e3655-cb50-477b-86ac-5e2e42b0f19d","acronym":"BP42675","url":"https://clinicaltrials.gov/study/NCT04826003","created_at":"2021-04-01T16:52:30.647Z","updated_at":"2024-07-02T16:34:37.780Z","phase":"Phase 1/2","brief_title":"Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment","source_id_and_acronym":"NCT04826003 - BP42675","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-06-06"},{"id":"43707759-e80d-422e-92b4-48c987e89ea1","acronym":"CARMEN-LC06","url":"https://clinicaltrials.gov/study/NCT05245071","created_at":"2022-02-17T18:22:23.864Z","updated_at":"2024-07-02T16:34:59.736Z","phase":"Phase 2","brief_title":"Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA","source_id_and_acronym":"NCT05245071 - CARMEN-LC06","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 03/06/2024","primary_completion_date":" 03/06/2024","study_txt":" Completion: 09/02/2024","study_completion_date":" 09/02/2024","last_update_posted":"2024-05-31"},{"id":"f2e7ae9c-fbe6-46c8-9a44-68c29c0586bb","acronym":"SGM-CBM","url":"https://clinicaltrials.gov/study/NCT04755920","created_at":"2021-02-16T12:53:46.630Z","updated_at":"2024-07-02T16:35:04.579Z","phase":"Phase 2","brief_title":"SGM-101 in Colorectal Brain Metastases.","source_id_and_acronym":"NCT04755920 - SGM-CBM","lead_sponsor":"Leiden University Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-09"},{"id":"345523f2-eb95-47c4-aa63-da74c79fb6fc","acronym":"EVEREST-1","url":"https://clinicaltrials.gov/study/NCT05736731","created_at":"2023-02-21T15:01:17.869Z","updated_at":"2024-07-02T16:35:10.811Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT05736731 - EVEREST-1","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • HLA-A*02","tags":["HLA-A • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e A2B530"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-04-09"},{"id":"0fe1e661-e6ba-4ae8-8932-832c728d7b6b","acronym":"INTRUSION","url":"https://clinicaltrials.gov/study/NCT05703555","created_at":"2023-01-30T18:59:46.055Z","updated_at":"2024-07-02T16:35:17.295Z","phase":"Phase 2","brief_title":"INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701","source_id_and_acronym":"NCT05703555 - INTRUSION","lead_sponsor":"Erasmus Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 02/16/2024","primary_completion_date":" 02/16/2024","study_txt":" Completion: 02/16/2024","study_completion_date":" 02/16/2024","last_update_posted":"2024-02-28"},{"id":"207f3b6a-911f-40e1-af15-23413b54bd20","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013111","created_at":"2023-08-28T14:08:22.937Z","updated_at":"2024-07-02T16:35:18.323Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors","source_id_and_acronym":"NCT06013111","lead_sponsor":"China Medical University, China","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti-CEA-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-02-21"},{"id":"ec924f14-828b-407b-8c51-af2c2883b940","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415475","created_at":"2023-11-14T16:14:28.256Z","updated_at":"2024-07-02T16:35:24.610Z","phase":"Phase 1","brief_title":"Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05415475","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • C-13-60"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 09/15/2024","primary_completion_date":" 09/15/2024","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2024-01-04"},{"id":"69f5854d-d9aa-44f3-9ec1-f34fb533f187","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245786","created_at":"2022-02-18T14:52:58.547Z","updated_at":"2024-07-02T16:35:30.698Z","phase":"Phase 1","brief_title":"An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05245786","lead_sponsor":"City of Hope Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 11/12/2025","primary_completion_date":" 11/12/2025","study_txt":" Completion: 11/12/2025","study_completion_date":" 11/12/2025","last_update_posted":"2023-11-01"},{"id":"2855f339-9b0d-49e8-bb3f-80feb3b6dbdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03324113","created_at":"2021-01-18T16:24:55.664Z","updated_at":"2024-07-02T16:35:58.002Z","phase":"Phase 1","brief_title":"Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT03324113","lead_sponsor":"Sanofi","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tusamitamab ravtansine (SAR408701)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/17/2017","start_date":" 10/17/2017","primary_txt":" Primary completion: 11/18/2022","primary_completion_date":" 11/18/2022","study_txt":" Completion: 12/26/2022","study_completion_date":" 12/26/2022","last_update_posted":"2023-01-09"},{"id":"7645761f-f4b8-47f4-83e9-d65ee6dfcd9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05619562","created_at":"2022-11-17T15:57:39.394Z","updated_at":"2024-07-02T16:36:00.274Z","phase":"","brief_title":"Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients","source_id_and_acronym":"NCT05619562","lead_sponsor":"The Institute of Molecular and Translational Medicine, Czech Republic","biomarkers":" EGFR • MET • CEACAM5 • EPCAM","pipe":" | ","alterations":" EGFR expression • CEACAM5 expression • EPCAM expression","tags":["EGFR • MET • CEACAM5 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CEACAM5 expression • EPCAM expression"],"overall_status":"Completed","enrollment":" Enrollment 166","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2022-11-17"},{"id":"2970cc81-805c-417e-8aae-d4e7ccdaa0c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02587247","created_at":"2021-01-18T12:33:08.299Z","updated_at":"2024-07-02T16:36:06.688Z","phase":"Phase 2","brief_title":"ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer","source_id_and_acronym":"NCT02587247","lead_sponsor":"Nantes University Hospital","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TF2"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2022-07-26"},{"id":"cf042111-c026-42d8-bfbb-bbf21966b009","acronym":"","url":"https://clinicaltrials.gov/study/NCT03682744","created_at":"2021-01-18T18:03:27.452Z","updated_at":"2024-07-02T16:36:13.862Z","phase":"Phase 1","brief_title":"CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)","source_id_and_acronym":"NCT03682744","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2022-04-06"},{"id":"93f87e57-9718-4f29-b02f-982fc7f27fd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04037241","created_at":"2021-01-18T19:48:33.373Z","updated_at":"2024-07-02T16:36:14.266Z","phase":"Phase 2b","brief_title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer \u0026 Liver Metastases","source_id_and_acronym":"NCT04037241","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • gene-modified anti-CEA T cells"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-04-01"},{"id":"d5bd476e-4483-4deb-b32f-69fd38ad5a3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05240950","created_at":"2022-02-15T15:52:41.969Z","updated_at":"2024-07-02T16:36:15.534Z","phase":"Phase 1","brief_title":"Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases","source_id_and_acronym":"NCT05240950","lead_sponsor":"Changhai Hospital","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/25/2022","start_date":" 08/25/2022","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 12/25/2026","study_completion_date":" 12/25/2026","last_update_posted":"2022-03-11"},{"id":"6057d5a5-8252-4e03-8807-9ee477a97a89","acronym":"HITM-SURE","url":"https://clinicaltrials.gov/study/NCT02850536","created_at":"2021-01-18T13:59:34.702Z","updated_at":"2024-07-02T16:36:22.633Z","phase":"Phase 1","brief_title":"CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer","source_id_and_acronym":"NCT02850536 - HITM-SURE","lead_sponsor":"Roger Williams Medical Center","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gene-modified anti-CEA T cells"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 02/01/2017","start_date":" 02/01/2017","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 09/17/2021","study_completion_date":" 09/17/2021","last_update_posted":"2021-10-21"},{"id":"93901ec6-cb53-4006-986c-b326980ea647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501770","created_at":"2021-01-18T21:33:47.632Z","updated_at":"2024-07-02T16:36:26.942Z","phase":"Phase 1","brief_title":"A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04501770","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • CA 19-9","pipe":" | ","alterations":" HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/28/2021","start_date":" 08/28/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-08-04"},{"id":"8de56a8f-2ad2-4af5-bc14-736a9721360e","acronym":"ANSR-PDAC","url":"https://clinicaltrials.gov/study/NCT04915417","created_at":"2021-06-07T15:53:25.453Z","updated_at":"2024-07-02T16:36:28.778Z","phase":"","brief_title":"Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04915417 - ANSR-PDAC","lead_sponsor":"Lawson Health Research Institute","biomarkers":" PD-L1 • CD8 • CEACAM5","pipe":" | ","alterations":" PD-L1 expression • CD8 expression • CEACAM5 expression","tags":["PD-L1 • CD8 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 expression • CEACAM5 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-06-22"},{"id":"07b4179f-e8ed-4410-a9f7-220b1ee391d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501744","created_at":"2021-01-18T21:33:47.040Z","updated_at":"2024-07-02T16:36:42.300Z","phase":"Phase 1","brief_title":"A Study of M701 (EpCAM and CD3) in Malignant Ascites","source_id_and_acronym":"NCT04501744","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" CEACAM5 • MUC16 • AFP • CA 19-9","pipe":" | ","alterations":" CEACAM5 expression • MUC16 expression","tags":["CEACAM5 • MUC16 • AFP • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • MUC16 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M701"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2020-08-06"},{"id":"4fed5445-16f5-4afc-a23e-a964c229154d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02324257","created_at":"2021-01-18T11:01:30.196Z","updated_at":"2024-07-02T16:36:45.906Z","phase":"Phase 1","brief_title":"A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors","source_id_and_acronym":"NCT02324257","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • cibisatamab (RG7802)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 12/30/2014","start_date":" 12/30/2014","primary_txt":" Primary completion: 09/03/2019","primary_completion_date":" 09/03/2019","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-04-17"},{"id":"9d759b1e-1179-43f0-84f0-2e00510ccf08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840994","created_at":"2021-01-18T13:56:43.083Z","updated_at":"2024-07-02T16:36:49.478Z","phase":"Phase 1","brief_title":"A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02840994","lead_sponsor":"Bavarian Nordic","biomarkers":" ALK • ROS1 • CEACAM5","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression","tags":["ALK • ROS1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-02-27"},{"id":"6081c37d-f019-4e99-ac44-93bef698131a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650713","created_at":"2021-01-18T12:54:17.706Z","updated_at":"2024-07-02T16:36:50.148Z","phase":"Phase 1","brief_title":"A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors","source_id_and_acronym":"NCT02650713","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cibisatamab (RG7802)"],"overall_status":"Completed","enrollment":" Enrollment 228","initiation":"Initiation: 01/07/2016","start_date":" 01/07/2016","primary_txt":" Primary completion: 01/13/2020","primary_completion_date":" 01/13/2020","study_txt":" Completion: 01/13/2020","study_completion_date":" 01/13/2020","last_update_posted":"2020-02-12"},{"id":"a0325957-4da9-40a5-b181-00dd056940d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02350673","created_at":"2021-01-18T11:10:56.487Z","updated_at":"2024-07-02T16:36:51.298Z","phase":"Phase 1b","brief_title":"A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors","source_id_and_acronym":"NCT02350673","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD8 • CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CD8 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cergutuzumab amunaleukin (RG7813)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 12/16/2019","primary_completion_date":" 12/16/2019","study_txt":" Completion: 12/16/2019","study_completion_date":" 12/16/2019","last_update_posted":"2020-01-18"},{"id":"7ed986a6-8873-40bc-9db3-ba423395efce","acronym":"","url":"https://clinicaltrials.gov/study/NCT03337347","created_at":"2021-01-18T16:29:11.301Z","updated_at":"2024-07-02T16:36:54.547Z","phase":"","brief_title":"Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients","source_id_and_acronym":"NCT03337347","lead_sponsor":"The Institute of Molecular and Translational Medicine, Czech Republic","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression"],"overall_status":"Completed","enrollment":" Enrollment 256","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 02/28/2007","primary_completion_date":" 02/28/2007","study_txt":" Completion: 10/23/2015","study_completion_date":" 10/23/2015","last_update_posted":"2019-10-15"}]